Aripiprazole Solution
Product Images NDC 72888-100

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 72888-100). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advagen Pharma Ltd, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazole Oral Solution (1 mg/ml) (NDC 72888-100-20)

Aripiprazole Oral Solution 1 mg/mL packaging label shows a 150 mL bottle distributed by Advagen Pharma Limited. The label includes dosing instructions, storage conditions, and a reminder to dispense the enclosed Medication Guide. The product NDC is 72888-100-20, and it is Rx Only.*

FDA Label Image

Aripiprazole Oral Solution (1 mg/ml) (NDC 72888-100-20)

Label for Aripiprazole Oral Solution 1 mg/mL distributed by Advagen Pharma Limited. The label indicates a 150 mL bottle with storage instructions and a barcode. It includes an instruction to dispense the enclosed Medication Guide to patients and the product is marked Rx Only.*

FDA Label Image

8f42eff5-figure-01 (Aripiprazole Oral Solution Chem Structure)

Chemical structure diagram of Aripiprazole showing its molecular composition and arrangement, including two chlorine atoms, a piperazine ring, and a quinolinone moiety linked by a butoxy chain.*

FDA Label Image

1 (Aripiprazole Oral Solution Fig1)

A chart titled 'Effect of Other Drugs on Aripiprazole' showing the fold change and 90% confidence interval of Aripiprazole pharmacokinetic parameters (AUC and Cmax) relative to a reference without interacting drugs. It compares the impact of several interacting drugs including ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam on Aripiprazole exposure.*

FDA Label Image

1 (Aripiprazole Oral Solution Fig2)

A pharmacokinetic chart titled "Effect of Other Drugs on Aripiprazole" showing the fold change in dehydro-aripiprazole levels with 90% confidence intervals. It compares changes in AUC and Cmax relative to a reference without interacting drugs, for various inhibitors, inducers, acid blockers, and other drugs including ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam.*

FDA Label Image

1 (Aripiprazole Oral Solution Fig3)

A forest plot chart titled 'Effect of Aripiprazole on Other Drugs' showing fold change and 90% confidence intervals for various drugs and enzymes. The x-axis represents 'Change Relative to Reference (without interacting drug)' ranging from 0.5 to 3, depicting pharmacokinetic parameters such as AUC and Cmax for drugs including dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and escitalopram with respect to their change when combined with Aripiprazole.*

FDA Label Image

1 (Aripiprazole Oral Solution Fig4)

A pharmacokinetic chart titled 'Aripiprazole Fold Change and 90% CI' showing the change relative to reference for special populations. It compares AUC and Cmax values between different groups, including CYP2D6 metabolizers, gender, age categories, hepatic impairment levels, and severe renal impairment, with fold changes and confidence intervals plotted along a horizontal axis.*

FDA Label Image

1 (Aripiprazole Oral Solution Fig5)

A forest plot chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' illustrating pharmacokinetic comparisons of AUC and Cmax between various groups. Variables include CYP2D6 metabolizer status, gender, age, hepatic impairment severity, and severe renal impairment, with fold change on the x-axis relative to a reference value of 1.*

FDA Label Image

1 (Aripiprazole Oral Solution Fig6)

A Kaplan-Meier survival curve chart depicting the proportion of subjects experiencing relapse over time (days from randomization) comparing Aripiprazole and placebo groups. The graph includes a risk table beneath showing the number of subjects remaining at risk at various time points. The solid line represents Aripiprazole, while the dashed line represents placebo.*

FDA Label Image

1 (Aripiprazole Oral Solution Fig7)

A Kaplan-Meier survival curve chart depicting the proportion of subjects with relapse over days from randomization. Two groups are compared: Aripiprazole and placebo. The horizontal axis shows days from 0 to 182, and the vertical axis shows the proportion with relapse from 0 to 1. The number of subjects at risk is listed below the timeline for each group. The Aripiprazole group shows a lower proportion with relapse over time compared to placebo, as indicated by separate curves for each group.*

FDA Label Image

1 (Aripiprazole Oral Solution Fig8)

A Kaplan-Meier curve showing the proportion of subjects with relapse over days from randomization comparing Aripiprazole and placebo groups. The graph plots the relapse proportion on the vertical axis against days from randomization on the horizontal axis, with the number of subjects at risk listed below the timeline for each group.*

FDA Label Image

1 (Aripiprazole Oral Solution Fig9)

A line graph showing the least-squares mean change in YGTSS total TIC score from baseline over 8 weeks of treatment. The graph compares three groups: ARIP-LOW, ARIP-HIGH, and PLACEBO, with ARIP-HIGH showing the greatest decrease, followed by ARIP-LOW, and PLACEBO showing the least change. The x-axis represents weeks of treatment, and the y-axis represents the change in TIC score.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.